Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNUMDG)

• Drug Name: BW A4C Drug Info
• Synonyms: BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 6438354
  ChEBI ID: CHEMBL314360
  CAS Number: CAS 106328-57-8
  TTD Drug ID: DMNUMDG

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[4]
Diethylcarbamazine	DM1TJ8F	Elephantiasis		Approved	[5]
Silymarin	DMXBYQR	N. A.	N. A.	Phase 4	[6]
3,4-Dihydroxycinnamic Acid	DMVZL26	Thrombocytopenia	3B64	Phase 4	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
ABT-761	DM3FIC2	Asthma	CA23	Phase 3	[9]
Tenidap	DMHQRYE	Rheumatoid arthritis	FA20	Phase 3	[10]
FPL-62064	DMGF8MZ	Inflammation	1A00-CA43.1	Phase 3	[11]
Flobufen	DMPSG4D	Rheumatoid arthritis	FA20	Phase 3	[12]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[13]

Drug(s) Targeting LOX-5 messenger RNA (ALOX5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TEBUFELONE	DMMUE8P	Pain	MG30-MG3Z	Discontinued in Phase 2	[14]
ZD-2138	DMVFCX7	Asthma	CA23	Discontinued in Phase 2	[15]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[16]
2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	DMWNJ84	Discovery agent	N.A.	Investigative	[17]
METHYLHONOKIOL	DM9YE6K	Discovery agent	N.A.	Investigative	[17]
HONOKIOL	DMJWT3X	Discovery agent	N.A.	Investigative	[17]
PUUPEHEDIONE	DMF28IU	Discovery agent	N.A.	Investigative	[18]
PUUPEHENONE	DMF3BCK	Discovery agent	N.A.	Investigative	[18]
Isojaspic acid	DMHTBDN	Discovery agent	N.A.	Investigative	[18]
5,3'-Dipropyl-biphenyl-2,4'-diol	DMJRXLD	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Inhibitor	[2]
LOX-5 messenger RNA (ALOX5 mRNA)	TTSJ6Q4	LOX5_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000230)
• [2] Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Oncogene. 2009 Jul 23;28(29):2690-6.
• [3] Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem. 2008 Sep 11;51(17):5449-53.
• [4] 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
• [5] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [6] Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
• [7] Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
• [8] Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
• [9] Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
• [10] The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
• [11] FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
• [12] Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
• [13] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [14] New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflam... J Med Chem. 1998 Aug 27;41(18):3515-29.
• [15] Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24.
• [16] Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62.
• [17] Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
• [18] Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63.